OpenGrowth: An Automated and Rational Algorithm for Finding New Protein Ligands

Journal of Medicinal Chemistry

Volumn 59, Issue 9, 2016, Pages 4171-4188

  Chéron, Nicolas ^a   Jasty, Naveen ^a   Shakhnovich, Eugene I ^a  

^a HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LIGAND; P16 PROTEASE, HUMAN IMMUNODEFICIENCY VIRUS 1;

ALGORITHM; ARTICLE; COMPUTER INTERFACE; COMPUTER PROGRAM; LIGAND BINDING; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; AUTOMATION; CHEMISTRY; SOFTWARE;

ALGORITHMS; AUTOMATION; HIV PROTEASE; HIV PROTEASE INHIBITORS; LIGANDS; SOFTWARE; USER-COMPUTER INTERFACE;

EID: 84969557103     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00886     Document Type: Article

References (133)

1. Cavasotto, C. N.; Phatak, S. S. Homology modeling in drug discovery: current trends and applications Drug Discovery Today 2009, 14 (13-14) 676-83 10.1016/j.drudis.2009.04.006
2. Mobley, D. L.; Klimovich, P. V. Perspective: Alchemical free energy calculations for drug discovery J. Chem. Phys. 2012, 137 (23) 230901 10.1063/1.4769292
3. Norinder, U.; Bergström, C. A. S. Prediction of ADMET Properties ChemMedChem 2006, 1 (9) 920-937 10.1002/cmdc.200600155
4. Kitchen, D. B.; Decornez, H.; Furr, J. R.; Bajorath, J. Docking and scoring in virtual screening for drug discovery: methods and applications Nat. Rev. Drug Discovery 2004, 3 (11) 935-49 10.1038/nrd1549
5. Waszkowycz, B.; Clark, D. E.; Gancia, E. Outstanding challenges in protein-ligand docking and structure-based virtual screening Wiley Interdisciplinary Reviews: Computational Molecular Science 2011, 1 (2) 229-259 10.1002/wcms.18
6. Irwin, J. J.; Shoichet, B. K. ZINC - a free database of commercially available compounds for virtual screening J. Chem. Inf. Model. 2005, 45 (1) 177-82 10.1021/ci049714+
7. Irwin, J. J.; Sterling, T.; Mysinger, M. M.; Bolstad, E. S.; Coleman, R. G. ZINC: a free tool to discover chemistry for biology J. Chem. Inf. Model. 2012, 52 (7) 1757-68 10.1021/ci3001277
8. Mullard, A. Drug repurposing programmes get lift off Nat. Rev. Drug Discovery 2012, 11 (7) 505-6 10.1038/nrd3776
9. Novac, N. Challenges and opportunities of drug repositioning Trends Pharmacol. Sci. 2013, 34 (5) 267-72 10.1016/j.tips.2013.03.004
10. Sardana, D.; Zhu, C.; Zhang, M.; Gudivada, R. C.; Yang, L.; Jegga, A. G. Drug repositioning for orphan diseases Briefings Bioinf. 2011, 12 (4) 346-56 10.1093/bib/bbr021
11. Riggs, B. L.; Hartmann, L. C. Selective estrogen-receptor modulators-mechanisms of action and application to clinical practice N. Engl. J. Med. 2003, 348 (7) 618-29 10.1056/NEJMra022219
12. Vogel, V. G.; Costantino, J. P.; Wickerham, D. L.; Cronin, W. M.; Cecchini, R. S.; Atkins, J. N.; Bevers, T. B.; Fehrenbacher, L.; Pajon, E. R., Jr.; Wade, J. L., 3rd; Robidoux, A.; Margolese, R. G.; James, J.; Lippman, S. M.; Runowicz, C. D.; Ganz, P. A.; Reis, S. E.; McCaskill-Stevens, W.; Ford, L. G.; Jordan, V. C.; Wolmark, N. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial Jama 2006, 295 (23) 2727-41 10.1001/jama.295.23.joc60074
13. Clavel, F.; Hance, A. J. HIV drug resistance N. Engl. J. Med. 2004, 350 (10) 1023-35 10.1056/NEJMra025195
14. Hachmann, J.; Olivares-Amaya, R.; Atahan-Evrenk, S.; Amador-Bedolla, C.; Sánchez-Carrera, R. S.; Gold-Parker, A.; Vogt, L.; Brockway, A. M.; Aspuru-Guzik, A. The Harvard Clean Energy Project: Large-Scale Computational Screening and Design of Organic Photovoltaics on the World Community Grid J. Phys. Chem. Lett. 2011, 2 (17) 2241-2251 10.1021/jz200866s
15. Tew, G. N.; Scott, R. W.; Klein, M. L.; DeGrado, W. F. De Novo Design of Antimicrobial Polymers, Foldamers, and Small Molecules: From Discovery to Practical Applications Acc. Chem. Res. 2010, 43 (1) 30-39 10.1021/ar900036b
16. Hartenfeller, M.; Schneider, G. Enabling future drug discovery by de novo design Wiley Interdisciplinary Reviews: Computational Molecular Science 2011, 1 (5) 742-759 10.1002/wcms.49
17. Hartenfeller, M.; Schneider, G. De novo drug design Methods Mol. Biol. 2010, 672, 299-323 10.1007/978-1-60761-839-3-12
18. Honma, T. Recent advances in de novo design strategy for practical lead identification Med. Res. Rev. 2003, 23 (5) 606-32 10.1002/med.10046
19. Kutchukian, P. S.; Shakhnovich, E. I. De novo design: balancing novelty and confined chemical space Expert Opin. Drug Discovery 2010, 5 (8) 789-812 10.1517/17460441.2010.497534
20. Loving, K.; Alberts, I.; Sherman, W. Computational approaches for fragment-based and de novo design Curr. Top. Med. Chem. 2010, 10 (1) 14-32 10.2174/156802610790232305
21. Mauser, H.; Guba, W. Recent developments in de novo design and scaffold hopping Curr. Opin. Drug Discovery Dev. 2008, 11 (3) 365-74
22. Schneider, G.; Fechner, U. Computer-based de novo design of drug-like molecules Nat. Rev. Drug Discovery 2005, 4 (8) 649-63 10.1038/nrd1799
23. Schneider, G.; Hartenfeller, M.; Reutlinger, M.; Tanrikulu, Y.; Proschak, E.; Schneider, P. Voyages to the (un)known: adaptive design of bioactive compounds Trends Biotechnol. 2009, 27 (1) 18-26 10.1016/j.tibtech.2008.09.005
24. Zaliani, A.; Boda, K.; Seidel, T.; Herwig, A.; Schwab, C. H.; Gasteiger, J.; Claussen, H.; Lemmen, C.; Degen, J.; Parn, J.; Rarey, M. Second-generation de novo design: a view from a medicinal chemist perspective J. Comput.-Aided Mol. Des. 2009, 23 (8) 593-602 10.1007/s10822-009-9291-2
25. Schneider, G. De Novo Molecular Design; Wiley-VCH: Weinheim, Germany, 2013.
26. Bohm, H. J. The computer program LUDI: a new method for the de novo design of enzyme inhibitors J. Comput.-Aided Mol. Des. 1992, 6 (1) 61-78 10.1007/BF00124387
27. Huang, Q.; Li, L.-L.; Yang, S.-Y. PhDD: A new pharmacophore-based de novo design method of drug-like molecules combined with assessment of synthetic accessibility J. Mol. Graphics Modell. 2010, 28 (8) 775-787 10.1016/j.jmgm.2010.02.002
28. Pierce, A. C.; Rao, G.; Bemis, G. W. BREED: Generating Novel Inhibitors through Hybridization of Known Ligands. Application to CDK2, P38, and HIV Protease J. Med. Chem. 2004, 47 (11) 2768-2775 10.1021/jm030543u
29. Fechner, U.; Schneider, G. Flux (1): A Virtual Synthesis Scheme for Fragment-Based de Novo Design J. Chem. Inf. Model. 2006, 46 (2) 699-707 10.1021/ci0503560
30. Fechner, U.; Schneider, G. Flux (2): Comparison of molecular mutation and crossover operators for ligand-based de novo design J. Chem. Inf. Model. 2007, 47 (2) 656-667 10.1021/ci6005307
31. Lewell, X. Q.; Judd, D. B.; Watson, S. P.; Hann, M. M. RECAP - retrosynthetic combinatorial analysis procedure: a powerful new technique for identifying privileged molecular fragments with useful applications in combinatorial chemistry J. Chem. Inf. Model. 1998, 38 (3) 511-22 10.1021/ci970429i
32. Lameijer, E. W.; Kok, J. N.; Back, T.; Ijzerman, A. P. The molecule evoluator. An interactive evolutionary algorithm for the design of drug-like molecules J. Chem. Inf. Model. 2006, 46 (2) 545-52 10.1021/ci050369d
33. Devi, R. V.; Sathya, S. S.; Coumar, M. S. Evolutionary algorithms for de novo drug design-A survey Applied Soft Computing 2015, 27 (0) 543-552 10.1016/j.asoc.2014.09.042
34. Durrant, J. D.; Amaro, R. E.; McCammon, J. A. AutoGrow: A Novel Algorithm for Protein Inhibitor Design Chem. Biol. Drug Des. 2009, 73 (2) 168-178 10.1111/j.1747-0285.2008.00761.x
35. Durrant, J. D.; Lindert, S.; McCammon, J. A. AutoGrow 3.0: An improved algorithm for chemically tractable, semi-automated protein inhibitor design J. Mol. Graphics Modell. 2013, 44 (0) 104-112 10.1016/j.jmgm.2013.05.006
36. Pearce, B. C.; Langley, D. R.; Kang, J.; Huang, H.; Kulkarni, A. E-Novo: An Automated Workflow for Efficient Structure-Based Lead Optimization J. Chem. Inf. Model. 2009, 49 (7) 1797-1809 10.1021/ci900073k
37. Kutchukian, P. S.; Lou, D.; Shakhnovich, E. I. FOG: Fragment Optimized Growth algorithm for the de novo generation of molecules occupying druglike chemical space J. Chem. Inf. Model. 2009, 49 (7) 1630-42 10.1021/ci9000458
38. Nishibata, Y.; Itai, A. Automatic creation of drug candidate structures based on receptor structure. Starting point for artificial lead generation Tetrahedron 1991, 47 (43) 8985-8990 10.1016/S0040-4020(01)86503-0
39. Rotstein, S.; Murcko, M. GenStar: A method for de novo drug design J. Comput.-Aided Mol. Des. 1993, 7 (1) 23-43 10.1007/BF00141573
40. Luo, Z.; Wang, R.; Lai, L. RASSE: a new method for structure-based drug design J. Chem. Inf. Model. 1996, 36 (6) 1187-94 10.1021/ci950277w
41. Rotstein, S. H.; Murcko, M. A. GroupBuild: a fragment-based method for de novo drug design J. Med. Chem. 1993, 36 (12) 1700-1710 10.1021/jm00064a003
42. Bohacek, R. S.; McMartin, C. Multiple Highly Diverse Structures Complementary to Enzyme Binding Sites: Results of Extensive Application of a de Novo Design Method Incorporating Combinatorial Growth J. Am. Chem. Soc. 1994, 116 (13) 5560-5571 10.1021/ja00092a006
43. DeWitte, R. S.; Shakhnovich, E. I. SMoG: de Novo Design Method Based on Simple, Fast, and Accurate Free Energy Estimates. 1. Methodology and Supporting Evidence J. Am. Chem. Soc. 1996, 118 (47) 11733-11744 10.1021/ja960751u
44. DeWitte, R. S.; Ishchenko, A. V.; Shakhnovich, E. I. SMoG: de Novo Design Method Based on Simple, Fast, and Accurate Free Energy Estimates. 2. Case Studies in Molecular Design J. Am. Chem. Soc. 1997, 119 (20) 4608-4617 10.1021/ja963689+
45. Grzybowski, B. A.; Ishchenko, A. V.; Kim, C.-Y.; Topalov, G.; Chapman, R.; Christianson, D. W.; Whitesides, G. M.; Shakhnovich, E. I. Combinatorial computational method gives new picomolar ligands for a known enzyme Proc. Natl. Acad. Sci. U. S. A. 2002, 99 (3) 1270-1273 10.1073/pnas.032673399
46. Barreiro, G.; Kim, J. T.; Guimaraes, C. R.; Bailey, C. M.; Domaoal, R. A.; Wang, L.; Anderson, K. S.; Jorgensen, W. L. From docking false-positive to active anti-HIV agent J. Med. Chem. 2007, 50 (22) 5324-9 10.1021/jm070683u
47. Jorgensen, W. L. Efficient drug lead discovery and optimization Acc. Chem. Res. 2009, 42 (6) 724-33 10.1021/ar800236t
48. Jorgensen, W. L.; Ruiz-Caro, J.; Tirado-Rives, J.; Basavapathruni, A.; Anderson, K. S.; Hamilton, A. D. Computer-aided design of non-nucleoside inhibitors of HIV-1 reverse transcriptase Bioorg. Med. Chem. Lett. 2006, 16 (3) 663-7 10.1016/j.bmcl.2005.10.038
49. Degen, J.; Rarey, M. FlexNovo: Structure-Based Searching in Large Fragment Spaces ChemMedChem 2006, 1 (8) 854-868 10.1002/cmdc.200500102
50. Wang, R.; Gao, Y.; Lai, L. LigBuilder: A Multi-Purpose Program for Structure-Based Drug Design J. Mol. Model. 2000, 6 (7-8) 498-516 10.1007/s0089400060498
51. Yuan, Y.; Pei, J.; Lai, L. LigBuilder 2: a practical de novo drug design approach J. Chem. Inf. Model. 2011, 51 (5) 1083-91 10.1021/ci100350u
52. Ishchenko, A.; Liu, Z.; Lindblom, P.; Wu, G.; Jim, K. C.; Gregg, R. D.; Claremon, D. A.; Singh, S. B. Structure-based design technology contour and its application to the design of renin inhibitors J. Chem. Inf. Model. 2012, 52 (8) 2089-97 10.1021/ci200605k
53. Lindblom, P. R.; Wu, G.; Liu, Z.; Jim, K. C.; Baldwin, J. J.; Gregg, R. E.; Claremon, D. A.; Singh, S. B. An electronic environment and contact direction sensitive scoring function for predicting affinities of protein-ligand complexes in Contour((R)) J. Mol. Graphics Modell. 2014, 53, 118-27 10.1016/j.jmgm.2014.07.010
54. Vinkers, H. M.; de Jonge, M. R.; Daeyaert, F. F. D.; Heeres, J.; Koymans, L. M. H.; van Lenthe, J. H.; Lewi, P. J.; Timmerman, H.; Van Aken, K.; Janssen, P. A. J. SYNOPSIS: SYNthesize and OPtimize System in Silico J. Med. Chem. 2003, 46 (13) 2765-2773 10.1021/jm030809x
55. Hartenfeller, M.; Zettl, H.; Walter, M.; Rupp, M.; Reisen, F.; Proschak, E.; Weggen, S.; Stark, H.; Schneider, G. DOGS: reaction-driven de novo design of bioactive compounds PLoS Comput. Biol. 2012, 8 (2) e1002380 10.1371/journal.pcbi.1002380
56. Metropolis, N.; Rosenbluth, A. W.; Rosenbluth, M. N.; Teller, A. H.; Teller, E. Equation of State Calculations by Fast Computing Machines J. Chem. Phys. 1953, 21 (6) 1087-1092 10.1063/1.1699114
57. Bento, A. P.; Gaulton, A.; Hersey, A.; Bellis, L. J.; Chambers, J.; Davies, M.; Krüger, F. A.; Light, Y.; Mak, L.; McGlinchey, S.; Nowotka, M.; Papadatos, G.; Santos, R.; Overington, J. P. The ChEMBL bioactivity database: an update Nucleic Acids Res. 2014, 42 (D1) D1083-D1090 10.1093/nar/gkt1031
58. Aldeghi, M.; Malhotra, S.; Selwood, D. L.; Chan, A. W. E. Two- and Three-dimensional Rings in Drugs Chem. Biol. Drug Des. 2014, 83 (4) 450-461 10.1111/cbdd.12260
59. Taylor, R. D.; MacCoss, M.; Lawson, A. D. G. Rings in Drugs J. Med. Chem. 2014, 57 (14) 5845-5859 10.1021/jm4017625
60. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, G. A.; Nakatsuji, H.; Caricato, M.; Li, X.; Hratchian, H. P.; Izmaylov, A. F.; Bloino, J.; Zheng, G.; Sonnenberg, J. L.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Vreven, T.; Montgomery, J. A., Jr.; Peralta, J. E.; Ogliaro, F.; Bearpark, M. J.; Heyd, J.; Brothers, E. N.; Kudin, K. N.; Staroverov, V. N.; Kobayashi, R.; Normand, J.; Raghavachari, K.; Rendell, A. P.; Burant, J. C.; Iyengar, S. S.; Tomasi, J.; Cossi, M.; Rega, N.; Millam, N. J.; Klene, M.; Knox, J. E.; Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Martin, R. L.; Morokuma, K.; Zakrzewski, V. G.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Dapprich, S.; Daniels, A. D.; Farkas, Ö.; Foresman, J. B.; Ortiz, J. V.; Cioslowski, J.; Fox, D. J. Gaussian 09, revision A.02; Gaussian, Inc.: Wallingford, CT, U.S., 2009.
61. Zhao, Y.; Truhlar, D. The M06 suite of density functionals for main group thermochemistry, thermochemical kinetics, noncovalent interactions, excited states, and transition elements: two new functionals and systematic testing of four M06-class functionals and 12 other functionals Theor. Chem. Acc. 2008, 120 (1-3) 215-241 10.1007/s00214-007-0310-x
62. Dunning, T. H. Gaussian basis sets for use in correlated molecular calculations. I. The atoms boron through neon and hydrogen J. Chem. Phys. 1989, 90 (2) 1007-1023 10.1063/1.456153
63. Kendall, R. A.; Dunning, T. H.; Harrison, R. J. Electron affinities of the first-row atoms revisited. Systematic basis sets and wave functions J. Chem. Phys. 1992, 96 (9) 6796-6806 10.1063/1.462569
64. Tomasi, J.; Mennucci, B.; Cancès, E. The IEF version of the PCM solvation method: an overview of a new method addressed to study molecular solutes at the QM ab initio level J. Mol. Struct.: THEOCHEM 1999, 464 (1-3) 211-226 10.1016/S0166-1280(98)00553-3
65. Totrov, M.; Abagyan, R. Flexible ligand docking to multiple receptor conformations: a practical alternative Curr. Opin. Struct. Biol. 2008, 18 (2) 178-184 10.1016/j.sbi.2008.01.004
66. Cavasotto, C. N.; Abagyan, R. A. Protein Flexibility in Ligand Docking and Virtual Screening to Protein Kinases J. Mol. Biol. 2004, 337 (1) 209-225 10.1016/j.jmb.2004.01.003
67. Henzler, A. M.; Rarey, M. In Pursuit of Fully Flexible Protein-Ligand Docking: Modeling the Bilateral Mechanism of Binding Mol. Inf. 2010, 29 (3) 164-173 10.1002/minf.200900078
68. Mizutani, M. Y.; Takamatsu, Y.; Ichinose, T.; Nakamura, K.; Itai, A. Effective handling of induced-fit motion in flexible docking Proteins: Struct., Funct., Genet. 2006, 63 (4) 878-891 10.1002/prot.20931
69. Jiang, F.; Kim, S.-H. Soft docking: Matching of molecular surface cubes J. Mol. Biol. 1991, 219 (1) 79-102 10.1016/0022-2836(91)90859-5
70. Sherman, W.; Day, T.; Jacobson, M. P.; Friesner, R. A.; Farid, R. Novel Procedure for Modeling Ligand/Receptor Induced Fit Effects J. Med. Chem. 2006, 49 (2) 534-553 10.1021/jm050540c
71. Kokh, D. B.; Wenzel, W. Flexible Side Chain Models Improve Enrichment Rates in In Silico Screening J. Med. Chem. 2008, 51 (19) 5919-5931 10.1021/jm800217k
72. Zhao, Y.; Sanner, M. F. FLIPDock: Docking flexible ligands into flexible receptors Proteins: Struct., Funct., Genet. 2007, 68 (3) 726-737 10.1002/prot.21423
73. Bottegoni, G.; Kufareva, I.; Totrov, M.; Abagyan, R. Four-Dimensional Docking: A Fast and Accurate Account of Discrete Receptor Flexibility in Ligand Docking J. Med. Chem. 2009, 52 (2) 397-406 10.1021/jm8009958
74. Fischer, M.; Coleman, R. G.; Fraser, J. S.; Shoichet, B. K. Incorporation of protein flexibility and conformational energy penalties in docking screens to improve ligand discovery Nat. Chem. 2014, 6 (7) 575-583 10.1038/nchem.1954
75. Österberg, F.; Morris, G. M.; Sanner, M. F.; Olson, A. J.; Goodsell, D. S. Automated docking to multiple target structures: Incorporation of protein mobility and structural water heterogeneity in AutoDock Proteins: Struct., Funct., Genet. 2002, 46 (1) 34-40 10.1002/prot.10028
76. Teague, S. J. Implications of protein flexibility for drug discovery Nat. Rev. Drug Discovery 2003, 2 (7) 527-541 10.1038/nrd1129
77. Carlson, H. A. Protein flexibility and drug design: how to hit a moving target Curr. Opin. Chem. Biol. 2002, 6 (4) 447-452 10.1016/S1367-5931(02)00341-1
78. Koshland, D. E. Application of a Theory of Enzyme Specificity to Protein Synthesis Proc. Natl. Acad. Sci. U. S. A. 1958, 44 (2) 98-104 10.1073/pnas.44.2.98
79. Ishchenko, A. V.; Shakhnovich, E. I. SMall Molecule Growth 2001 (SMoG2001): An Improved Knowledge-Based Scoring Function for Protein-Ligand Interactions J. Med. Chem. 2002, 45 (13) 2770-2780 10.1021/jm0105833
80. Wright, D. W.; Hall, B. A.; Kenway, O. A.; Jha, S.; Coveney, P. V. Computing Clinically Relevant Binding Free Energies of HIV-1 Protease Inhibitors J. Chem. Theory Comput. 2014, 10 (3) 1228-1241 10.1021/ct4007037
81. Van Der Spoel, D.; Lindahl, E.; Hess, B.; Groenhof, G.; Mark, A. E.; Berendsen, H. J. GROMACS: fast, flexible, and free J. Comput. Chem. 2005, 26 (16) 1701-18 10.1002/jcc.20291
82. Hess, B.; Kutzner, C.; van der Spoel, D.; Lindahl, E. GROMACS 4: Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation J. Chem. Theory Comput. 2008, 4, 435-447 10.1021/ct700301q
83. Pronk, S.; Pall, S.; Schulz, R.; Larsson, P.; Bjelkmar, P.; Apostolov, R.; Shirts, M. R.; Smith, J. C.; Kasson, P. M.; van der Spoel, D.; Hess, B.; Lindahl, E. GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit Bioinformatics 2013, 29 (7) 845-54 10.1093/bioinformatics/btt055
84. Abraham, M. J.; Murtola, T.; Schulz, R.; Páll, S.; Smith, J. C.; Hess, B.; Lindahl, E. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers SoftwareX 2015, 1-2, 19-25 10.1016/j.softx.2015.06.001
85. Duan, Y.; Wu, C.; Chowdhury, S.; Lee, M. C.; Xiong, G.; Zhang, W.; Yang, R.; Cieplak, P.; Luo, R.; Lee, T.; Caldwell, J.; Wang, J.; Kollman, P. A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations J. Comput. Chem. 2003, 24 (16) 1999-2012 10.1002/jcc.10349
86. Jorgensen, W. L. Quantum and Statistical Mechanical Studies of Liquids. 10. Transferable Intermolecular Potential Functions for Water, Alcohols, and Ethers. Application to Liquid Water J. Am. Chem. Soc. 1981, 103, 335-340 10.1021/ja00392a016
87. Jorgensen, W. L.; Chandrasekhar, J.; Madura, J. D.; Impey, R. D.; Klein, M. L. Comparison of simple potential functions for simulating liquid water J. Chem. Phys. 1983, 79, 926 10.1063/1.445869
88. Protein Preparation Wizard, Schrödinger Release 2014-3; Schrödinger, LLC: New York, NY, 2014.
89. Madhavi Sastry, G.; Adzhigirey, M.; Day, T.; Annabhimoju, R.; Sherman, W. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments J. Comput.-Aided Mol. Des. 2013, 27 (3) 221-234 10.1007/s10822-013-9644-8
90. Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Couch, G. S.; Greenblatt, D. M.; Meng, E. C.; Ferrin, T. E. UCSF Chimera - a visualization system for exploratory research and analysis J. Comput. Chem. 2004, 25 (13) 1605-12 10.1002/jcc.20084
91. Wang, J.; Wang, W.; Kollman, P. A.; Case, D. A. Automatic atom type and bond type perception in molecular mechanical calculations J. Mol. Graphics Modell. 2006, 25 (2) 247-260 10.1016/j.jmgm.2005.12.005
92. Wang, J.; Wolf, R. M.; Caldwell, J. W.; Kollman, P. A.; Case, D. A. Development and testing of a general amber force field J. Comput. Chem. 2004, 25 (9) 1157-1174 10.1002/jcc.20035
93. Sousa da Silva, A.; Vranken, W. ACPYPE-AnteChamber PYthon Parser interfacE BMC Res. Notes 2012, 5 (1) 367 10.1186/1756-0500-5-367
94. Darden, T.; York, D.; Pedersen, L. Particle mesh Ewald: An N.log(N) method for Ewald sums in large systems J. Chem. Phys. 1993, 98, 10089-10092 10.1063/1.464397
95. Bussi, G.; Zykova-Timan, T.; Parrinello, M. Isothermal-isobaric molecular dynamics using stochastic velocity rescaling J. Chem. Phys. 2009, 130, 074101 10.1063/1.3073889
96. Nose, S. A unified formulation of the constant temperature molecular dynamics methods J. Chem. Phys. 1984, 81, 511 10.1063/1.447334
97. Hoover, W. G. Canonical dynamics: Equilibrium phase-space distributions Phys. Rev. A: At., Mol., Opt. Phys. 1985, 31 (3) 1695-1697 10.1103/PhysRevA.31.1695
98. Berendsen, H. J. C.; Postma, J. P. M.; van Gunsteren, W. F.; DiNola, A.; Haak, J. R. Molecular dynamics with coupling to an external bath J. Chem. Phys. 1984, 81, 3684 10.1063/1.448118
99. Parrinello, M.; Rahman, A. Polymorphic transitions in single crystals: A new molecular dynamics method J. Appl. Phys. 1981, 52, 7182 10.1063/1.328693
100. Hess, B. P-LINCS: A Parallel Linear Constraint Solver for Molecular Simulation J. Chem. Theory Comput. 2008, 4 (1) 116-122 10.1021/ct700200b
101. Hess, B.; Bekker, H.; Berendsen, H. J. C.; Fraaije, J. G. E. M. LINCS: A linear constraint solver for molecular simulations J. Comput. Chem. 1997, 18 (12) 1463-1472 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
102. Case, D. A.; Cheatham, T. E.; Darden, T.; Gohlke, H.; Luo, R.; Merz, K. M.; Onufriev, A.; Simmerling, C.; Wang, B.; Woods, R. J. The Amber biomolecular simulation programs J. Comput. Chem. 2005, 26 (16) 1668-1688 10.1002/jcc.20290
103. Pearlman, D. A.; Case, D. A.; Caldwell, J. W.; Ross, W. S.; Cheatham, T. E., III; DeBolt, S.; Ferguson, D.; Seibel, G.; Kollman, P. AMBER, a package of computer programs for applying molecular mechanics, normal mode analysis, molecular dynamics and free energy calculations to simulate the structural and energetic properties of molecules Comput. Phys. Commun. 1995, 91 (1-3) 1-41 10.1016/0010-4655(95)00041-D
104. Salomon-Ferrer, R.; Case, D. A.; Walker, R. C. An overview of the Amber biomolecular simulation package Wiley Interdisciplinary Reviews: Computational Molecular Science 2013, 3 (2) 198-210 10.1002/wcms.1121
105. Case, D. A.; Darden, T. A.; Cheatham, T. E.; Simmerling, C. L.; Wang, J.; Duke, R. E.; Luo, R.; Walker, R. C.; Zhang, W.; Merz, K. M.; Roberts, B.; Hayik, S.; Roitberg, A.; Seabra, G.; Swails, J.; Goetz, A. W.; Kolossváry, I.; Wong, K. F.; Paesani, F.; Vanicek, J.; Wolf, R. M.; Liu, J.; Wu, X.; Brozell, S. R.; Steinbrecher, T.; Gohlke, H.; Cai, Q.; Ye, X.; Wang, J.; Hsieh, M. J.; Cui, G.; Roe, D. R.; Mathews, D. H.; Seetin, M. G.; Salomon-Ferrer, R.; Sagui, C.; Babin, V.; Luchko, T.; Gusarov, S.; Kovalenko, A.; Kollman, P. A. AMBER 12; University of California, San Francisco, CA, 2012.
106. Miller, B. R.; McGee, T. D.; Swails, J. M.; Homeyer, N.; Gohlke, H.; Roitberg, A. E. MMPBSA.py: An Efficient Program for End-State Free Energy Calculations J. Chem. Theory Comput. 2012, 8 (9) 3314-3321 10.1021/ct300418h
107. Hou, T.; Yu, R. Molecular Dynamics and Free Energy Studies on the Wild-type and Double Mutant HIV-1 Protease Complexed with Amprenavir and Two Amprenavir-Related Inhibitors: Mechanism for Binding and Drug Resistance J. Med. Chem. 2007, 50 (6) 1177-1188 10.1021/jm0609162
108. Hou, T.; Wang, J.; Li, Y.; Wang, W. Assessing the Performance of the MM/PBSA and MM/GBSA Methods. 1. The Accuracy of Binding Free Energy Calculations Based on Molecular Dynamics Simulations J. Chem. Inf. Model. 2011, 51 (1) 69-82 10.1021/ci100275a
109. Rastelli, G.; Rio, A. D.; Degliesposti, G.; Sgobba, M. Fast and accurate predictions of binding free energies using MM-PBSA and MM-GBSA J. Comput. Chem. 2010, 31 (4) 797-810 10.1002/jcc.21372
110. Xu, L.; Sun, H.; Li, Y.; Wang, J.; Hou, T. Assessing the Performance of MM/PBSA and MM/GBSA Methods. 3. The Impact of Force Fields and Ligand Charge Models J. Phys. Chem. B 2013, 117 (28) 8408-8421 10.1021/jp404160y
111. Sun, H.; Li, Y.; Tian, S.; Xu, L.; Hou, T. Assessing the performance of MM/PBSA and MM/GBSA methods. 4. Accuracies of MM/PBSA and MM/GBSA methodologies evaluated by various simulation protocols using PDBbind data set Phys. Chem. Chem. Phys. 2014, 16 (31) 16719-16729 10.1039/C4CP01388C
112. Ratner, L.; Haseltine, W.; Patarca, R.; Livak, K. J.; Starcich, B.; Josephs, S. F.; Doran, E. R.; Rafalski, J. A.; Whitehorn, E. A.; Baumeister, K.; Ivanoff, L.; Petteway, S. R.; Pearson, M. L.; Lautenberger, J. A.; Papas, T. S.; Ghrayeb, J.; Chang, N. T.; Gallo, R. C.; Wong-Staal, F. Complete nucleotide sequence of the AIDS virus, HTLV-III Nature 1985, 313 (6000) 277-284 10.1038/313277a0
113. McGee, T. D.; Edwards, J.; Roitberg, A. E. pH-REMD Simulations Indicate That the Catalytic Aspartates of HIV-1 Protease Exist Primarily in a Monoprotonated State J. Phys. Chem. B 2014, 118 (44) 12577-12585 10.1021/jp504011c
114. Kim, E. E.; Baker, C. T.; Dwyer, M. D.; Murcko, M. A.; Rao, B. G.; Tung, R. D.; Navia, M. A. Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme J. Am. Chem. Soc. 1995, 117 (3) 1181-1182 10.1021/ja00108a056
115. Clemente, J. C.; Coman, R. M.; Thiaville, M. M.; Janka, L. K.; Jeung, J. A.; Nukoolkarn, S.; Govindasamy, L.; Agbandje-McKenna, M.; McKenna, R.; Leelamanit, W.; Goodenow, M. M.; Dunn, B. M. Analysis of HIV-1 CRF-01 A/E Protease Inhibitor Resistance: Structural Determinants for Maintaining Sensitivity and Developing Resistance to Atazanavir† Biochemistry 2006, 45 (17) 5468-5477 10.1021/bi051886s
116. Yedidi, R. S.; Maeda, K.; Fyvie, W. S.; Steffey, M.; Davis, D. A.; Palmer, I.; Aoki, M.; Kaufman, J. D.; Stahl, S. J.; Garimella, H.; Das, D.; Wingfield, P. T.; Ghosh, A. K.; Mitsuya, H. P2′ Benzene Carboxylic Acid Moiety Is Associated with Decrease in Cellular Uptake: Evaluation of Novel Nonpeptidic HIV-1 Protease Inhibitors Containing P2 bis-Tetrahydrofuran Moiety Antimicrob. Agents Chemother. 2013, 57 (10) 4920-4927 10.1128/AAC.00868-13
117. Chen, Z.; Li, Y.; Chen, E.; Hall, D. L.; Darke, P. L.; Culberson, C.; Shafer, J. A.; Kuo, L. C. Crystal structure at 1.9-A resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524, an orally bioavailable inhibitor of the HIV proteases J. Biol. Chem. 1994, 269 (42) 26344-26348
118. Šašková, K. G.; Kožíšek, M.; Lepšík, M.; Brynda, J.; Řezáčová, P.; Václavíková, J.; Kagan, R. M.; Machala, L.; Konvalinka, J. Enzymatic and structural analysis of the I47A mutation contributing to the reduced susceptibility to HIV protease inhibitor lopinavir Protein Sci. 2008, 17 (9) 1555-1564 10.1110/ps.036079.108
119. Kaldor, S. W.; Kalish, V. J.; Davies, J. F.; Shetty, B. V.; Fritz, J. E.; Appelt, K.; Burgess, J. A.; Campanale, K. M.; Chirgadze, N. Y.; Clawson, D. K.; Dressman, B. A.; Hatch, S. D.; Khalil, D. A.; Kosa, M. B.; Lubbehusen, P. P.; Muesing, M. A.; Patick, A. K.; Reich, S. H.; Su, K. S.; Tatlock, J. H. Viracept (Nelfinavir Mesylate, AG1343): A Potent, Orally Bioavailable Inhibitor of HIV-1 Protease J. Med. Chem. 1997, 40 (24) 3979-3985 10.1021/jm9704098
120. Kempf, D. J.; Marsh, K. C.; Denissen, J. F.; McDonald, E.; Vasavanonda, S.; Flentge, C. A.; Green, B. E.; Fino, L.; Park, C. H.; Kong, X. P. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans Proc. Natl. Acad. Sci. U. S. A. 1995, 92 (7) 2484-2488 10.1073/pnas.92.7.2484
121. Krohn, A.; Redshaw, S.; Ritchie, J. C.; Graves, B. J.; Hatada, M. H. Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere J. Med. Chem. 1991, 34 (11) 3340-3342 10.1021/jm00115a028
122. Muzammil, S.; Armstrong, A. A.; Kang, L. W.; Jakalian, A.; Bonneau, P. R.; Schmelmer, V.; Amzel, L. M.; Freire, E. Unique Thermodynamic Response of Tipranavir to Human Immunodeficiency Virus Type 1 Protease Drug Resistance Mutations J. Virol. 2007, 81 (10) 5144-5154 10.1128/JVI.02706-06
123. Stoll, V.; Qin, W.; Stewart, K. D.; Jakob, C.; Park, C.; Walter, K.; Simmer, R. L.; Helfrich, R.; Bussiere, D.; Kao, J.; Kempf, D.; Sham, H. L.; Norbeck, D. W. X-ray crystallographic structure of ABT-378 (Lopinavir) bound to HIV-1 protease Bioorg. Med. Chem. 2002, 10 (8) 2803-2806 10.1016/S0968-0896(02)00051-2
124. OBoyle, N.; Banck, M.; James, C.; Morley, C.; Vandermeersch, T.; Hutchison, G. Open Babel: An open chemical toolbox J. Cheminf. 2011, 3 (1) 33 10.1186/1758-2946-3-33
125. Hutter, M. C. Separating Drugs from Nondrugs: A Statistical Approach Using Atom Pair Distributions J. Chem. Inf. Model. 2007, 47 (1) 186-194 10.1021/ci600329u
126. Boda, K.; Seidel, T.; Gasteiger, J. Structure and reaction based evaluation of synthetic accessibility J. Comput.-Aided Mol. Des. 2007, 21 (6) 311-25 10.1007/s10822-006-9099-2
127. Sylvia, version r11685; Molecular Networks, GmbH: Erlangen, Germany, 2015.
128. Wess, G.; Urmann, M.; Sickenberger, B. Medicinal Chemistry: Challenges and Opportunities Angew. Chem., Int. Ed. 2001, 40 (18) 3341-3350 10.1002/1521-3773(20010917)40:18<3341::AID-ANIE3341>3.0.CO;2-D
129. QikProp, Small-Molecule Drug Discovery Suite 2014-3; Schrödinger, LLC: New York, NY, 2014.
130. Fässler, A.; Rösel, J.; Grüther, M.; Tintelnot-Blomley, M.; Atteri, E.; Bold, G.; Lang, M. Novel pseudosymmetric inhibitors of HIV-1 protease Bioorg. Med. Chem. Lett. 1993, 3 (12) 2837-2842 10.1016/S0960-894X(01)80775-7
131. Fässler, A.; Bold, G.; Capraro, H.-G.; Cozens, R.; Mestan, J.; Poncioni, B.; Rösel, J.; Tintelnot-Blomley, M.; Lang, M. Aza-Peptide Analogs as Potent Human Immunodeficiency Virus Type-1 Protease Inhibitors with Oral Bioavailability J. Med. Chem. 1996, 39 (16) 3203-3216 10.1021/jm960022p
132. Bold, G.; Fässler, A.; Capraro, H.-G.; Cozens, R.; Klimkait, T.; Lazdins, J.; Mestan, J.; Poncioni, B.; Rösel, J.; Stover, D.; Tintelnot-Blomley, M.; Acemoglu, F.; Beck, W.; Boss, E.; Eschbach, M.; Hürlimann, T.; Masso, E.; Roussel, S.; Ucci-Stoll, K.; Wyss, D.; Lang, M. New Aza-Dipeptide Analogues as Potent and Orally Absorbed HIV-1 Protease Inhibitors: Candidates for Clinical Development J. Med. Chem. 1998, 41 (18) 3387-3401 10.1021/jm970873c
133. Huey, R.; Morris, G. M.; Olson, A. J.; Goodsell, D. S. A semiempirical free energy force field with charge-based desolvation J. Comput. Chem. 2007, 28 (6) 1145-1152 10.1002/jcc.20634